There are lots of studies/trials out there that address this question. If you want a valid answer you should be looking there in large populations and scientific analysis rather than asking for one-off, anecdotal responses here. JMO.

Here is a link to one such study:
https://pubmed.ncbi.nlm.nih.gov/31909690/
and here is the abstract:

Abstract
Purpose: To study the risk of metastatic prostate cancer development in men with Grade Group 2
disease being managed with active surveillance (AS) at Memorial Sloan Kettering Cancer Center.
Materials and Methods: 219 men with Grade Group 2 prostate cancer were managed with AS
between 2000–2017. Biopsy was performed every 2–3 years or upon changes in magnetic
resonance imaging, prostate-specific antigen (PSA) level, or digital rectal examination. The
primary outcome was development of distant metastasis. The Kaplan-Meier method was used to
estimate treatment-free survival.
Results: The median age at diagnosis was 67 years (IQR 61, 72), the median PSA was 5 ng/mL
(IQR 4, 7), and most patients (69%) had non-palpable disease. During follow-up, 64 men received
treatment: 36/64 (56%) radical prostatectomy; 20/64 (31%) radiotherapy; 3/64 (5%) hormone
therapy; and 5/64 (8%) focal therapy. Of the 36 patients who underwent radical prostatectomy,
32/36 (89%) had Grade Group 2 disease on pathology and 4/36 (11%) had Grade Group 3.
Treatment-free survival was 61% (95% CI 52%–70%) at 5 years and 49% (95% CI 37%–60%) at
10 years. Three men experienced biochemical recurrence, no men developed distant metastasis,
and no men died of prostate cancer during the follow-up. The median follow-up was 3.1 years
(IQR 1.9, 4.9).

The key takeaway is: "Treatment-free survival was 61% (95% CI 52%–70%) at 5 years and 49% (95% CI 37%–60%) at 10 years."

Caution: This overall result is with all types of Grade Group 2 subgroups rolled up into one. The details of your pathology and imaging might mean you could expect shorter or longer times until you haveto seek treatment.